Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biohaven Pharmaceutical Holding Company Ltd (NY: BHVN )

84.91 USD -6.84 (-7.46%)
Official Closing Price Updated: 7:00 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 580,540
Open 91.24
Bid (Size) 83.27 (3)
Ask (Size) 84.60 (10)
Prev. Close 91.75
Today's Range 84.47 - 92.39
52wk Range 26.56 - 100.77
Shares Outstanding 36,017,573
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs
- Acquires full ownership of Kleo Pharmaceuticals with two novel immune modulating platforms: the Multi-targeted Antibody Therapy Enhancer (MATE™) conjugation platform and Antibody Recruiting Molecule... 
From PR Newswire
Biohaven's Nurtec® ODT Partners with Rick Ware Racing for 24 Hours of Daytona Entry
Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Nurtec® ODT (rimegepant) will be the primary sponsor on the #51 Ligier JS P217 entry into the LMP2 class of the 2021 24 Hours of Daytona.... 
From PR Newswire

Performance

YTD
+3.66%
+3.66%
1 Month
-5.29%
-5.29%
3 Month
+8.96%
+8.96%
6 Month
+16.73%
+16.73%
1 Year
+64.24%
+64.24%

More News

Read More
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
From PR Newswire
Biohaven's Rimegepant For Preventive Treatment Of Migraine Published In The Lancet
From PR Newswire
Kleo Pharmaceuticals Presents Preclinical Data on KPMW135, a Novel CD3 x CD20 Bispecific Version of Rituximab, Showing Increased Anti-Tumor Activity Compared to Rituximab, at The 62nd Annual American
From GlobeNewswire News Releases
Biohaven's Nurtec™ ODT Partners with the Rick Ware Racing Team in the 2021 NASCAR Cup Series
From PR Newswire
Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio
From PR Newswire
Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE™) at The 62nd Annual Society of Hematology (ASH) Meeting
From GlobeNewswire News Releases
BioShin enrolls first patient into an Asia-Pacific regional multi-center phase III clinical trial of rimegepant (BHV-3000) for the acute treatment of migraine.
From GlobeNewswire News Releases
Cramer Advises Viewers On Autodesk, Inseego And More
Tags MRVL Small Cap BHVN
From Benzinga
Biohaven Pharmaceutical Holding Enters Oversold Territory (BHVN)
Tags Stocks
From Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.